(Q38153344)

29 August 2017

title

What can we learn about schizophrenia from studying the human model, drug-induced psychosis? (English)

1 reference

29 August 2017

0 references

1 reference

1

1 reference

29 August 2017

Marta Di Forti

5

0 references

author name string

Alessandra Paparelli

series ordinal

2

1 reference

29 August 2017

Paul D Morrison

series ordinal

3

1 reference

29 August 2017

Arianna Marconi

series ordinal

4

1 reference

29 August 2017

publication date

1 October 2013

1 reference

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

29 August 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

29 August 2017

volume

162B

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

661-670

1 reference

Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Amphetamine psychosis: behavioral and biochemical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Dependence and psychosis with 4-methylmethcathinone (mephedrone) use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Endocannabinoid-mediated synaptic plasticity in the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Genetic association studies of methamphetamine use disorders: A systematic review and synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

What causes the onset of psychosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Dopamine-mediated regulation of corticostriatal synaptic plasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

A two-process theory of schizophrenia: evidence from studies in post-mortem brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Risk factors for schizophrenia--all roads lead to dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabis use and psychiatric and cogitive disorders: the chicken or the egg?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

High-potency cannabis and the risk of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Synthetic cannabinoid JWH-018 and psychosis: an explorative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Tryptamine, N,N-dimethyltryptamine, N,N-dimethyl-5-hydroxytryptamine and 5-methoxytryptamine in human blood and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The psychedelic model of schizophrenia: the case of N,N-dimethyltryptamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Dopaminergic sensitization: implications for the pathogenesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Psychedelics and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The basal ganglia: learning new tricks and loving it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: presentation of a case and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The environment and schizophrenia: the role of cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Legal highs on the Internet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Action selection and refinement in subcortical loops through basal ganglia and cerebellum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Neuromechanism of developing methamphetamine psychosis: a neuroimaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Khat chewing amongst UK resident male Yemeni adults: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Striatal plasticity and basal ganglia circuit function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

S39-02 Antipsychotic effects of cannabidiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Different effects of nabilone and cannabidiol on binocular depth inversion in Man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Provocative tests with psychostimulant drugs in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Serotonergic basis of antipsychotic drug effects in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Model psychoses and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Schizophrenia: from developmental deviance to dopamine dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

21 January 2018

Ketamine use: a review

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabis, the mind and society: the hash realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Increased excretion of dimethyltryptamine and certain features of psychosis: a possible association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Psychological effects of ketamine in healthy volunteers. Phenomenological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Prevalence of psychotic symptoms in substance users: a comparison across substances

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Human hallucinogenic drug research in the United States: a present-day case history and review of the process

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Can recreational doses of THC produce significant dopamine release in the human striatum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Dimethyltryptamin: its metabolism in man; the relation to its psychotic effect to the serotonin metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Phenotype of schizophrenia: a review and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Khat use among Somali mental health service users in South London

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabis use and psychosis: a longitudinal population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The environment and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

What should be done about mephedrone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

The role of the basal ganglia in habit formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabis, COMT and psychotic experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

History of cannabis as a medicine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabidiol for the treatment of psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Substance use in a population-based clinic sample of people with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32177

21 January 2018

Identifiers

DOI

10.1002/AJMG.B.32177

1 reference

29 August 2017

1 reference